BioSpace News Archive

Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS) Late-breaking data to be presented at ACR Convergence: the American College of Rheumatology/Association of Rheumatology Professionals’ Virtual Meeting

FibroGen, Inc. announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following healthcare conferences

- Third quarter net sales of $1.929 billion increased 2.0%, and increased 1.1% on a constant currency basis - Third quarter diluted earnings per share were $1.16; adjusted diluted earnings per share were $1.81

-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for JTX-1811- -Initiated the Phase 2 SELECT biomarker selection trial of vopratelimab in combination with JTX-4014- -Company to host conference call and webcast today at 8:00 AM ET-

The integration of healthcare IT solutions with EHR stands as the key factor promoting the growth of the global ambulatory EHR market during the forecast period, 2019 - 2029.

Next Generation Sequencing technology has made remarkable strides in clinical settings and in oncology research.

In recent years, major population from all across the globe is more vigilant about their aesthetics.

The global hemophilia gene therapy market is predicted to increase at a stellar pace in the years to follow.

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 . Even

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in a virtual fireside chat at the 29 th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2020 at 3:30 p.m. Eastern Time. A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.iron